Patent Number: 8,298,541

Title: Live attenuated virus vaccines for La Crosse virus and other Bunyaviridae

Abstract: The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACV) infection in a biological sample and infectious chimeric Bunyaviridae.

Inventors: Whitehead; Stephen S. (Bethesda, MD), Bennett; Richard S. (Chevy Chase, MD), Murphy; Brian R. (Bethesda, MD)

Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services

International Classification: A61K 39/12 (20060101); C12Q 1/70 (20060101); C12N 7/01 (20060101); C07K 14/175 (20060101); A61P 31/14 (20060101)

Expiration Date: 2020-10-30 0:00:00